Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 7/2016

01-07-2016 | Original Paper

Pre-exposure Prophylaxis Awareness Among Gay and Other Men who have Sex with Men in Vancouver, British Columbia, Canada

Authors: Nathan J. Lachowsky, Sally Y. Lin, Mark W. Hull, Zishan Cui, Paul Sereda, Jody Jollimore, Ashleigh Rich, Julio S. G. Montaner, Eric A. Roth, Robert S. Hogg, David M. Moore

Published in: AIDS and Behavior | Issue 7/2016

Login to get access

Abstract

Men who have sex with men (MSM) account for approximately half of Canada’s new HIV infections. Pre-exposure prophylaxis (PrEP), a recently established and effective HIV prevention tool for MSM is currently not approved nor publicly funded. We recruited MSM via respondent-driven sampling to complete a self-administered computer-based interview. Stratified by HIV status, multivariable logistic regression identified factors associated with PrEP awareness. Of 673 participants, 102/500 (20.9 %) HIV-negative and 63/173 (26.5 %) HIV-positive men were aware of PrEP, but none had used it. One third of PrEP-aware MSM spoke about it with friends or sex partners. Self-declared knowledge was limited. Factors associated with PrEP awareness varied by HIV status, but included greater HAART optimism for HIV-negative MSM. Among HIV-negative MSM, being PrEP unaware was associated with younger age, not always having condoms, and preferring receptive versus insertive anal sex. Future longitudinal research should identify early adopters of PrEP and its associated impacts.
Literature
1.
Public Health Agency of Canada (PHAC). Population-specific HIV/AIDS Status Report: gay, bisexual, two-spirit and other men who have sex with men. Centre for Communicable Diseases and Infection Control. PHAC. 2013.
2.
Public Health Agency of Canada (PHAC). HIV and AIDS in Canada: Surveillance Report to December 31, 2013. Minister of Public Works and Government Services Canada. 2014.
3.
Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN. Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep. 2011;8(1):62–72.CrossRefPubMedPubMedCentral
4.
Grant R, Lama J, Anderson P, et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. N Engl J Med. 2010;30(363):2587–99.CrossRef
5.
Baeten JM, Donnell DD, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral
6.
Thigpen M, Kebaabetswe P, Paxton L, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;2(367):423–34.CrossRef
7.
8.
Marrazzo J, Ramjee G, Richardson B, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;11(372):509–18.CrossRef
9.
Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRefPubMed
10.
McCormack S & Dunn D. Pragmatic open-label randomised trial of preexposure prophylaxis: the PROUD study. In: Conference on retroviruses and opportunistic infections. 2015
11.
Molina JM, Capitatn C, Spire B, et al. On demand PrEP with oral TDF-FTC in MSM: Results of the ANRS Ipergay trial. In: Conference on retroviruses and opportunistic infections. 2015.
12.
13.
Kellerman SE, Hutchinson AB, Begley EB, Boyett BC, Clark HA, Sullivan P. Knowledge and use of HIV pre-exposure prophylaxis among attendees of minority gay pride events, 2004. J Acquir Immune Defic Syndr. 2006;43(3):376–7.CrossRefPubMed
14.
Al-Tayyib AA, Thrun MW, Haukoos JS, Walls NE. Knowledge of pre-exposure prophylaxis (PrEP) for HIV prevention among men who have sex with men in Denver Colorado. AIDS Behav. 2014;18(S3):340–7.CrossRefPubMedPubMedCentral
15.
Galindo G, Walker J, Hazelton P, et al. Community member perspectives from transgender women and men who have sex with men on pre-exposure prophylaxis as an HIV prevention strategy: implications for implementation. Implement Sci. 2012;7(1):116.CrossRefPubMedPubMedCentral
16.
Golub S, Kowalczyk W, Weinberger C, Parsons J. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54(5):548–55.CrossRefPubMedPubMedCentral
17.
Krakower DS, Mimiaga MJ, Rosenberger JG, et al. Limited awareness and low immediate uptake of pre-exposure prophylaxis among men who have sex with men using an internet social networking site. PLoS ONE. 2012;7(3):e33119.CrossRefPubMedPubMedCentral
18.
Liu A, Kittredge P, Vittinghoff E, et al. Limited knowledge and use of hiv post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr. 2008;47(2):241–7.CrossRefPubMed
19.
Mimiaga M, Case P, Johnson C, Safren S, Mayer K. Preexposure antiretroviral prophylaxis attitudes in high-risk boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009;50(1):77–83.CrossRefPubMedPubMedCentral
20.
Nodin N, Carballo-Diéguez A, Ventuneac AM, Balan IC, Remien R. Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback. AIDS Care. 2008;20(1):106–15.CrossRefPubMed
21.
Rucinski K, Mensah N, Sepkowitz K, Cutler B, Sweeney M, Myers J. Knowledge and use of pre-exposure prophylaxis among an online sample of young men who have sex with men in New York city. AIDS Behav. 2013;17(6):2180–4.CrossRefPubMed
22.
Mayer KH, Oldenburg CE, Novak DS, Elsesser SA, Krakower DS, Mimiaga MJ. Early Adopters: Correlates of HIV Chemoprophylaxis Use in Recent Online Samples of US Men Who Have Sex with Men. AIDS Behav. 2015. doi:10.​1007/​s10461-015-1237-1.
23.
Lourenço L, Lima VD, Heath K, et al. Process monitoring of an HIV treatment as prevention program in British Columbia, Canada. J Acquir Immune Defic Syndr. 2014;67(3):e94–109.CrossRefPubMedPubMedCentral
24.
Johnston KM, Levy AR, Lima VD, et al. Expanding access to HAART: a cost-effective approach for treating and preventing HIV. AIDS. 2010;24(12):1929–35.CrossRefPubMed
25.
Forrest JI, Stevenson B, Rich A, et al. Community mapping and respondent-driven sampling of gay and bisexual men’s communities in Vancouver, Canada. Cult Health Sex. 2014;16(3):288–301.CrossRef
26.
Van de Ven P, Crawford J, Kippax S, Knox S, Prestage G. A scale of optimism-scepticism in the context of HIV treatments. AIDS Care. 2000;12(2):171–6.CrossRefPubMed
27.
Nimmons D, Folkman S. Other-sensitive motivations for safer sex among gay men: expanding paradigms for HIV prevention. AIDS Behav. 1999;3:313–24.CrossRef
28.
Kalichman S, Rompa D. Sexual sensation seeking and sexual compulsivity scales: reliability, validity and predicting HIV risk behavior. J Pers Assess. 1995;65(3):586–601.CrossRefPubMed
29.
Volz E, Wejnert C, Cameron C, Spiller M, Barash V, Degani I, Heckathorn DD. Respondent-Driven Sampling Analysis Tool (RDSAT) Version 7.1. Ithaca: Cornell University; 2012.
30.
Heckathorn DD. A new approach to the study of hidden populations social problems. Soc Probl. 1977;4(2):174–99.
31.
Volz E, Heckathorn DD. Probability based estimation theory for respondent driven sampling. J Off Stat. 2008;24(1):79–97.
32.
Lima VD, Geller J, Bangsberg DR, et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS. 2007;9:1175–83.CrossRef
33.
Brown JL, Sales JM, DiClemente RJ. Combination HIV prevention interventions: the potential of integrated behavioral and biomedical approaches. Curr HIV/AIDS Rep. 2014;11(4):363–75.CrossRefPubMedPubMedCentral
34.
Snowden JM, Wei C, McFarland W. Prevalence, correlates and trends in seroadaptive behaviours among men who have sex with men from serial cross-sectional surveillance in San Francisco, 2004–2011. Sex Transm Infect. 2014;90(6):498–504.CrossRefPubMed
35.
36.
Leonardi M, Lee E, Tan DH. Awareness of, usage of and willingness to use HIV pre-exposure prophylaxis among men in downtown Toronto, Canada. Int J STD AIDS. 2011;22(12):738–41.CrossRefPubMed
37.
Rosser B, Wilkerson JM, Smolenski DJ, Oakes JM. The future of Internet-based HIV prevention: a report on key findings from the Men’s INTernet (MINTS-I, II) Sex Studies. AIDS Behav. 2011;15(S1):S91–100.CrossRefPubMed
Metadata
Title
Pre-exposure Prophylaxis Awareness Among Gay and Other Men who have Sex with Men in Vancouver, British Columbia, Canada
Authors
Nathan J. Lachowsky
Sally Y. Lin
Mark W. Hull
Zishan Cui
Paul Sereda
Jody Jollimore
Ashleigh Rich
Julio S. G. Montaner
Eric A. Roth
Robert S. Hogg
David M. Moore
Publication date
01-07-2016
Publisher
Springer US
Published in
AIDS and Behavior / Issue 7/2016
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1319-8

Other articles of this Issue 7/2016

AIDS and Behavior 7/2016 Go to the issue

Original Paper

Repeat Use of Post-exposure Prophylaxis for HIV Among Nairobi-Based Female Sex Workers Following Sexual Exposure

Original Paper

Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level in MTN-001: Comparison Between Vaginal Gel and Oral Tablets in Two Geographic Regions

Original Paper

The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study

Original Paper

Attitudes Toward HIV Pre-Exposure Prophylaxis in a United States Urban Clinic Population

Original Paper

Evaluating the Impact of the US National HIV/AIDS Strategy, 2010–2015

Erratum

Erratum to: Awareness of Pre-exposure Prophylaxis for HIV, Willingness to Use It and Potential Barriers or Facilitators to Uptake Among Men Who Have Sex with Men in Spain
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits